6,734 trials (keyword fallback)
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Non-Small Cell Lung Cancer
Primary: Prevalence of ALK Fusion — 27 Participants
Advanced Non-Small Cell Lung Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 94; 89 Participants
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
ALK-positive Non-small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Per Investigator Assessment — 35.7; 30.0; 50.0; 59.1 Percentage of participants
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001
Schizophrenia · Schizoaffective Disorder
Primary: Strauss-Carpenter Level of Function Scale — 97.69; 94.56 score on a scale
Non-small Cell Lung Cancer · Carcinoma · NSCLC
Primary: Number of Subjects With Treatment-emergent Adverse Events — 2; 1; 1; 0 participants
Childhood Solid Neoplasm · Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Neuroblastoma
Primary: Maximum Tolerated Dose (MTD) of Crizotinib — 215 mg/m^2
Anaplastic Large Cell Lymphoma, ALK-Positive · Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma · Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Primary: Occurrence of Grade 3+ Non-hematologic Adverse Events — 80.6; 87.9 Percentage of patients
Lymphoma
Primary: Event-free Survival (EFS) — 74; 79 percentage of participants
Anaplastic Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Number of Patients With Response — 0; 2 participants